Trial Opportunities
8 opportunities | 7 pending review | 3 high-scoring
TOTAL OPPORTUNITIES
8
PENDING REVIEW
7
1 under review
HIGH-SCORING
3
feasibility ≥ 80
TOTAL EST. REVENUE
$8.3M
| PROTOCOL | SPONSOR | THERAPEUTIC AREA | PHASE | TARGET ENROLLMENT | EST. REVENUE | FEASIBILITY | STATUS | |
|---|---|---|---|---|---|---|---|---|
ENDO-METAB-305 MetabFix Type 2 Diabetes Novel Treatment | MetabFix Therapeutics via PPD | Endocrinology | PHASE III | 80 28mo | $1600K $444K margin | 91 | PENDING | Review |
ONCO-NOVA-401 NovaCell Immunotherapy for Advanced NSCL... | NovaCell Therapeutics via Syneos Health | Oncology | PHASE III | 45 30mo | $1350K $328K margin | 88 | PENDING | Review |
CARDIO-APEX-202 ApexCardio Novel Anticoagulant for AFib | ApexCardio Pharmaceuticals via ICON plc | Cardiology | PHASE II | 60 24mo | $1200K $310K margin | 82 | UNDER REVIEW | Review |
PULMO-COPD-205 COPD Novel Bronchodilator Study | RespiCare Pharma via Medpace | Pulmonology | PHASE II | 40 22mo | $800K $173K margin | 79 | PENDING | Review |
NEURO-PATH-301 NeuroPath Advanced Parkinsons Therapy | NeuroPath Biosciences | Neurology | PHASE III | 35 36mo | $1225K $235K margin | 76 | PENDING | Review |
ONCO-BREAST-201 Breast Cancer Targeted Therapy Phase II | OncoCare Research | Oncology | PHASE II | 25 20mo | $625K $108K margin | 72 | PENDING | Review |
NEURO-MS-204 Multiple Sclerosis Progression Inhibitor | NeuroScience Global via PRA Health Sciences | Neurology | PHASE II | 30 32mo | $900K $133K margin | 69 | PENDING | Review |
CARDIO-HEART-101 Novel Heart Failure Gene Therapy Phase I | GenHeart Therapeutics | Cardiology | PHASE I | 15 18mo | $600K $53K margin | 64 | PENDING | Review |